셀비온

308430KOSDAQ의약품 제조업

41.3 / 100

Reference Date: 2026-06-10

Financial Score4.0 / 40

News Sentiment21.3 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 40.6% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Cellon focuses on developing radiopharmaceuticals using Theranostics technology to realize precision medicine, with Lu-177-Pocuvotide as a key drug for prostate cancer treatment and diagnosis. The company completed phase II clinical trials in South Korea and secured final results by late 2025, leveraging its expertise in designing radiopharmaceuticals targeting various proteins through an open innovation strategy.

Number of Employees

56people

Average Salary

50.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.934.0Point

PBR

10.15Industry Average 0.890.0Point

11.4x industry avg (risky)

ROE

-28.93Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

44.53Industry Average 12.430.0Point

3.6x industry avg (risky)

Trend 2024~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼15.1% (1-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼15.5% (1-year basis)

ROE Trend

0.0 / 4

Avg ROE -34.1% (improving, 2yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
셀비온, ASCO서 전립선암 치료제 임상 2상 발표...단독투여로 글로...
셀비온의 전립선암 치료제 임상 2상 결과가 ASCO에서 발표되어 우수한 생존율 지표를 보여주며 긍정적인 시장 반응을 이끌어냈다.
Positive
셀비온, 머크와 임상 본격화...임상 3상 수준으로 격상해 기술수출 정...
셀비온의 전립선암 치료제 임상 단계가 머크와의 협력으로 3상으로 진전되어 기술 수출 기대감이 높아짐.

Detailed Momentum

52-week position1.0Point

Near 52w low (8%, downtrend)

Current 17,930Won52-week high 40,15052-week low 15,980

1-month return0.0Point

1m -40.63% (strong drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-15
Neutral분기보고서 (2026.03)2026-05-14